Information Provided By: 
Fly News Breaks for March 27, 2017
EXAS
Mar 27, 2017 | 07:59 EDT
Cowen analyst Doug Schenkel initiated Exact Sciences with an Outperform and a $30 price target saying its Cologuard colon cancer screening product is targeting $4B of a $15B annual market opportunity and forcasts a 5-year revenue CAGR of 50%. The analyst said over the past several quarters, Exact Sciences has gained CMS reimbursement coverage, expanded commercial lives covered to 171M from 60M in one year, and demonstrated increasing commercial success with its salesforce and advertising campaigns.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
